Physician profile
Alok Kumar
NPI 1639373202
$8,663.83
in general payments reported to CMS, 2019-2025
32 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $914 · 2021: $998 · 2022: $1,158 · 2023: $1,069 · 2024: $1,682 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,411.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,747.38 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $770.74 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $631.54 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $578.81 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $555.32 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $430.27 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $372.79 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $369.76 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $327.58 | 2020-2025 | Caplyta |
| Lundbeck LLC | $319.89 | 2019-2024 | Rexulti |
| Corium, LLC | $279.37 | 2023-2025 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $248.17 | 2022-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $245.99 | 2019-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $204.78 | 2019-2025 | Trintellix |
| Alkermes, INC. | $204.33 | 2019-2025 | Aristada, Lybalvi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $200.45 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $194.23 | 2019-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $174.15 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $154.05 | 2019-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $103.51 | 2025 | Jornay Pm |
| Novo Nordisk INC | $97.48 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $77.06 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $73.40 | 2021-2025 | Zurzuvae |
| Adlon Therapeutics L.P. | $67.70 | 2020-2021 | |
| Almatica Pharma LLC | $60.46 | 2022-2023 | Venlafaxine, Sertraline Hcl, Citalopram |
| Indivior INC. | $41.22 | 2022-2024 | Perseris |
| Eisai INC. | $36.10 | 2020 | |
| Vertical Pharmaceuticals, LLC | $30.66 | 2024 | Relexxii |
| Jazz Pharmaceuticals INC. | $19.73 | 2022 | |
| Validus Pharmaceuticals LLC | $16.95 | 2022 | |
| Brainsway USA INC | $15.24 | 2023 | |
| Avanir Pharmaceuticals, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.